IGC Pharma (IGC) Net Equity Issued and Repurchased (2010 - 2025)
IGC Pharma (IGC) posted quarterly Net Equity Issued and Repurchased of $3.1 million for Q3 2025, up 291.32% year-over-year from $795000.0 in Q3 2024, and up 265.14% quarter-over-quarter from $852000.0 in Q2 2025.
IGC Pharma (IGC) Net Equity Issued and Repurchased (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Net Equity Issued and Repurchased for 15 consecutive years, with $3.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased rose 291.32% year-over-year to $3.1 million; the TTM figure through Sep 2025 stood at $5.1 million (up 47.38% YoY), while the FY2026 annual figure was $87000.0, down 98.05% from the prior year.
- Net Equity Issued and Repurchased advanced to $3.1 million in Q3 2025 per IGC's latest filing, from $852000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $14.2 million in Q1 2021 and bottomed at $103000.0 in Q3 2022.
- Historically, Net Equity Issued and Repurchased has averaged $2.5 million across 5 years, with a median of $828500.0 in 2025.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased jumped 18487.01% — and 2022, when it plunged 96.99%.
- IGC Pharma's Net Equity Issued and Repurchased stood at $3.4 million in 2021, then slumped by 96.99% to $103000.0 in 2022, then surged by 2676.7% to $2.9 million in 2023, then sank by 87.9% to $346000.0 in 2024, then surged by 799.13% to $3.1 million in 2025.
- Business Quant data shows IGC's Net Equity Issued and Repurchased at $3.1 million in Q3 2025, $852000.0 in Q2 2025, and $805000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.11 Mn |
| Sep 30, 2025 | 3.11 Mn |
| Jun 30, 2025 | 852,000.00 |
| Jun 30, 2025 | 852,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 346,000.00 |
| Dec 31, 2024 | 346,000.00 |
| Sep 30, 2024 | 795,000.00 |
| Sep 30, 2024 | 795,000.00 |
| Jun 30, 2024 | 2.51 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 167,000.00 |
| Mar 31, 2024 | 167,000.00 |
| Sep 30, 2023 | 2.86 Mn |
| Sep 30, 2023 | 2.86 Mn |
| Sep 30, 2022 | 103,000.00 |
| Sep 30, 2022 | 103,000.00 |
| Sep 30, 2021 | 3.42 Mn |
| Sep 30, 2021 | 3.42 Mn |